SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Aquestive Therapeutics Inc

Aquestive Therapeutics is experiencing heightened investor conversation as the FDA's decision date for its Anaphylm oral film rapidly approaches, with widespread optimism for the needle-free, highly portable epinephrine treatment. Community discussions center on the product's "game-changing" convenience and the potential for a significant short squeeze, actively countering skepticism from bearish positions.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is trending amidst a sharp pullback, primarily driven by increased CME margin requirements that triggered liquidations. A significant portion of the community views this as a buying opportunity, pointing to an impending China export ban, strong industrial demand from AI and EVs, and a perceived disparity between physical and paper silver prices. Conversely, many contend the recent surge was an unsustainable run, anticipating further volatility.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences (GLSI) is trending due to impressive preliminary Phase 3 trial results showing an 80% reduction in breast cancer recurrence, alongside an extended insider lock-up signaling strong management confidence. This news has ignited intense community discussion about its low float, extremely high cost to borrow, and significant short interest, leading to widespread speculation of a substantial short squeeze and a potential multi-billion dollar valuation for its breast cancer therapy.

Sprott Physical Silver Trust - Units

Sprott Physical Silver Trust ET

PSLV is trending as community discussion focuses on a looming "silversqueeze" driven by accelerating industrial demand from sectors like AI and EVs, coupled with reported restrictions on silver exports from major producers. Investors are actively debating a growing global physical silver shortage and its potential for significantly higher prices, viewing physically-backed trusts like PSLV as a key play against market manipulation.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical (RARE) is trending due to significant market volatility after its bone disease drug, setrusumab, failed to meet primary endpoints in recent Phase 3 trials. The community is actively debating whether the ensuing sharp share price decline is an overreaction, pointing to the company's existing portfolio of approved therapies and robust pipeline. High trading volume reflects strong investor engagement as participants assess the company's revised valuation and potential for a rebound.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is actively trending as it prepares for upcoming presentations at CES 2026 and Qubits 2026, highlighting its quantum technology for optimization and its synergy with AI and blockchain. This focus on commercial readiness and its claimed "quantum supremacy" in optimization is driving significant community discussion, with some anticipating substantial future growth through potential partnerships, while others remain skeptical about its valuation and insider activity.

TryHard Holdings Ltd. is a lifestyle entertainment company that operates in Japan offering a diverse range of services across the entertainment and hospitality sectors. It operates through the following business segments: Consultancy and management, Event curation, Sub-leasing and Restaurants. The Consultancy and management segment provides expert services to clubs, including operations, event management, and strategic support to enhance performance and engagement. The Event curation segment organize and produce own events, also provides a full suite of services, including event planning, construction, entertainment booking, event operation, and ticket sales. The Sub-Leasing segment acts as an intermediary between landlords and clubs. The Restaurants segment operates several restaurants. The company was founded on October 16, 2013 and is headquartered in Osaka, Japan.

TryHard Holdings Ltd.

TryHard Holdings Ltd. (THH) is trending due to its recent NASDAQ IPO as a Japanese lifestyle entertainment company, sparking highly speculative trading and extreme volatility. The community is sharply divided, with some anticipating a significant short squeeze given its low float and reported high ROE, while others actively label it a pump-and-dump scheme often promoted in social media groups. This clash of sentiment is driving intense discussion and rapid price movements.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending following its pivotal FDA approval of YARTEMLEA, marking its first commercial product and the only approved therapy for transplant-associated thrombotic microangiopathy (TA-TMA). Community sentiment is highly bullish, anticipating significant long-term value and a potential short squeeze, fueled by the immediate January 2nd launch and a strong financial position from its Novo Nordisk partnership. Investors are keenly awaiting further details, including pricing and commercial strategy, expected from the upcoming conference call.

Mannatech, Inc. engages in the development of nutritional supplements, topical and skin care products and weight-management products that target optimal health and wellness. Its product category includes integrative health, targeted health, wealth and fitness, skin care, essentials, and home. The company was founded by Marlin Ray Robbins and Samuel L. Caster in November 1993 and is headquartered in Flower Mound, TX.

Mannatech Inc

Mannatech (MTEX) is trending amidst intense retail speculation, primarily fueled by its exceptionally low share float which the community believes could lead to a significant short squeeze. Traders are actively discussing its potential for rapid price appreciation, with some noting recent positive financial indicators and management actions as contributing factors to its anticipated breakout.

ImageneBio, Inc. is a clinical-stage biotechnology company that boldly imagines a world where patients can be free from the burden of grievous immunological/autoimmune and inflammatory (I&I) diseases. It focuses on the development of new medicines with differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The company was founded in February 2016, and is headquartered in San Diego, CA.

ImageneBio Inc.

ImageneBio, Inc.

ImageneBio (IMA) is trending due to highly divergent analyst ratings, with some initiating bullish coverage citing deep pipeline value and significant cash, while others warn of a long timeline to data and a lower valuation. The community is actively debating the company's substantial cash reserves and the long-term potential of its Phase 2b program for atopic dermatitis against the lack of near-term catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
